|
Market Closed -
Toronto S.E.
10:08:33 02/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 0.4100 CAD | +5.13% |
|
-2.38% | -9.89% |
| 02/10 | PharmaCorp Rx Closes Two New Acquisitions for About CA$1.8 Million | MT |
| 27/08 | Pharmacorp Rx Inc. Announces Board and Committee Changes, Effective from August 31, 2026 | CI |
Company Valuation: PharmaCorp Rx Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 63.34 | 75.95 | 80.76 | - | - |
| Change | - | 19.91% | 6.33% | - | - |
| Enterprise Value (EV) 1 | 63.34 | 53.55 | 87.37 | 88.21 | 85.13 |
| Change | - | -15.46% | 63.16% | 0.97% | -3.49% |
| P/E | -54x | -45.5x | 41x | 13.7x | - |
| PBR | - | - | - | - | - |
| PEG | - | - | -0x | 0x | - |
| Capitalization / Revenue | - | 3.64x | 1.62x | 0.84x | 0.95x |
| EV / Revenue | - | 2.56x | 1.75x | 0.92x | 1x |
| EV / EBITDA | - | 15.2x | 21.9x | 8.43x | 7.57x |
| EV / EBIT | - | - | 50.5x | 13.6x | 22.8x |
| EV / FCF | - | 27.9x | 193x | 17.3x | 11.6x |
| FCF Yield | - | 3.58% | 0.52% | 5.79% | 8.61% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -0.01 | -0.01 | 0.01 | 0.03 | - |
| Distribution rate | - | - | - | - | - |
| Net sales 1 | - | 20.89 | 49.96 | 95.97 | 85.37 |
| EBITDA 1 | - | 3.528 | 3.988 | 10.46 | 11.24 |
| EBIT 1 | - | - | 1.731 | 6.508 | 3.737 |
| Net income 1 | -1.013 | -1.481 | 1.5 | 6.7 | - |
| Net Debt 1 | - | -22.4 | 6.603 | 7.451 | 4.371 |
| Reference price 2 | 0.5400 | 0.4550 | 0.4100 | 0.4100 | 0.4100 |
| Nbr of stocks (in thousands) | 1,17,296 | 1,66,927 | 1,96,981 | - | - |
| Announcement Date | 22/04/25 | 29/04/26 | - | - | - |
1CAD in Million2CAD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 41x | 1.56x | 17.83x | - | 5.01Cr | |
| 15.77x | 0.61x | 9.06x | -.--% | 1.41TCr | |
| 22.82x | 0.93x | 9.87x | 1.94% | 651.38Cr | |
| 15.73x | 0.7x | 7.3x | 2.37% | 606.22Cr | |
| 19.71x | 0.33x | 5.31x | 2.34% | 592.31Cr | |
| 19.11x | 0.71x | 12.09x | 0.94% | 579.89Cr | |
| 14.99x | 0.92x | 6.46x | 2.82% | 421.5Cr | |
| 14.25x | 1.23x | 7.55x | 5.68% | 315.43Cr | |
| 15.31x | 0.44x | 7.36x | 1.38% | 311.46Cr | |
| 13.96x | 0.59x | 4.54x | 5.17% | 309.14Cr | |
| Average | 19.27x | 0.80x | 8.74x | 2.52% | 520.03Cr | |
| Weighted average by Cap. | 17.21x | 0.69x | 8.20x | 1.86% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PCRX Stock
- Valuation PharmaCorp Rx Inc.
Select your edition
All financial news and data tailored to specific country editions
